First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).
- Citation:
- J Clin Oncol vol 32 (15_suppl) LBA4
- Meeting Instance:
- ASCO 2014
- Year:
- 2014
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2247
- Pharmas:
- Grants:
- Corr. Author:
- Martine J. Piccart-Gebhart
- Authors:
- Martine J. Piccart-Gebhart Andrew Peter Holmes Jose Baselga Evandro de Azambuja Amylou C. Dueck Giuseppe Viale Jo Anne Zujewski Aron Goldhirsch Sergio Santillana Kathleen I. Pritchard Antonio C. Wolff Christian Jackisch Istvan Lang Michael Untch Ian E. Smith Frances Boyle Binghe Xu Henry Leonidas Gomez Richard D. Gelber Edith A. Perez
- Networks:
- Study
- NCCTG-N063D
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: